DUBLIN – Shares in Pieris Pharmaceuticals Inc. rose 20 percent Friday on news of an immuno-oncology deal with Seattle Genetics Inc., which brings in $30 million up front and potentially up to $1.2 billion more in milestones spread across three programs. Boston-based Pieris would also receive tiered royalties that could reach a low double-digit percentage of product sales. It is also retaining a co-commercialization option covering the U.S. for the alliance's second program.